Rapid decline in bone turnover markers but not bone mineral density in acromegalic patients after transsphenoidal surgery

被引：16

作者：

Tamada, Daisuke ^{[1
]}

Kitamura, Tetsuhiro ^{[1
]}

Onodera, Toshiharu ^{[1
]}

Tabuchi, Yukiko ^{[1
]}

Fukuhara, Atsunori ^{[1
]}

Oshino, Satoru ^{[2
]}

Saitoh, Youichi ^{[2
]}

Hamasaki, Toshimitsu ^{[3
]}

Otsuki, Michio ^{[1
]}

Shimomura, Iichiro ^{[1
]}

机构：

[1] Osaka Univ, Grad Sch Med, Dept Metab Med, Suita, Osaka 5650871, Japan

[2] Osaka Univ, Grad Sch Med, Dept Neurosurg, Osaka 5650871, Japan

[3] Osaka Univ, Grad Sch Med, Dept Biomed Stat, Osaka 5650871, Japan

来源：

ENDOCRINE JOURNAL | 2014年 / 61卷 / 03期

关键词：

Acromegaly; Bone turnover marker; Bone mineral density; Transsphenoidal surgery; GROWTH-HORMONE REPLACEMENT; BODY-COMPOSITION; GH DEFICIENCY; IGF-I; GONADAL-FUNCTION; RECEPTOR GENE; HYPOPITUITARISM; PEGVISOMANT; ANTAGONIST; GENDER;

D O I：

10.1507/endocrj.EJ13-0387

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Growth hormone (GH) and insulin-like growth factor-I (IGF-I) play important roles in maintaining bone metabolism and bone mineral density (BMD) in adulthood, in addition to stimulating longitudinal bone growth in childhood. However, information on the effect of GH excess on bone metabolism and BMD is incomplete and requires further analysis. The aim of this study is to clarify the effect of rapid decline in GH levels after transsphenoidal surgery (TSS) on bone metabolism in acromegalic patients. In this prospective study, 22 patients (11 males and 11 females) with active acromegaly underwent TSS. Bone formation marker (serum bone alkaline phosphatase: BAP), bone resorption marker (urinary type I collagen cross-linked N-telopeptide: urinary NTx) and BMD were measured before and at 3 and 12 months after TSS. BAP was significantly decreased at 12 months after TSS, but not at 3 months. Urinary NTx was significantly decreased at 3 and 12 months after TSS. BMD did not change after TSS. In conclusion, the rapid fall in GH level after TSS had no effect on BMD for up to 12 months after TSS despite the decrease in markers of bone formation and resorption.

引用

页码：231 / 237

页数：7

共 23 条

[1] Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant [J].

Barkan, AL ;

Burman, P ;

Clemmons, DR ;

Drake, WM ;

Gagel, RF ;

Harris, PE ;

Trainer, PJ ;

van der Lely, AJ ;

Vance, ML .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (10) :5684-5691

[2] Bone mineral density and turnover in patients with acromegaly in relation to sex, disease activity, and gonadal function [J].

Bolanowski, M ;

Daroszewski, J ;

Medras, M ;

Zadrozna-Sliwka, B .

JOURNAL OF BONE AND MINERAL METABOLISM, 2006, 24 (01) :72-78

[3] Growth hormone treatment in adults with adult-onset growth hormone deficiency increases iliac crest trabecular bone turnover: A 1-year, double-blind, randomized, placebo-controlled study [J].

Brixen, K ;

Hansen, TB ;

Hauge, E ;

Vahl, N ;

Jorgensen, JOL ;

Christiansen, JS ;

Mosekilde, L ;

Hagen, C ;

Melsen, F .

JOURNAL OF BONE AND MINERAL RESEARCH, 2000, 15 (02) :293-300

[4] Consequences of lifetime isolated growth hormone (GH) deficiency and effects of short-term GH treatment on bone in adults with a mutation in the GHRH-receptor gene [J].

de Paula, Francisco J. A. ;

Gois-Junior, Miburge B. ;

Aguiar-Oliveira, Manuel H. ;

Pereira, Francisco de A. ;

Oliveira, Carla R. P. ;

Pereira, Rossana M. C. ;

Farias, Catarine T. ;

Vicente, Tabita A. R. ;

Salvatori, Roberto .

CLINICAL ENDOCRINOLOGY, 2009, 70 (01) :35-40

[5] Effects of a growth hormone receptor antagonist on bone markers in acromegaly [J].

Fairfield, WP ;

Sesmilo, G ;

Katznelson, L ;

Pulaski, K ;

Freda, PU ;

Stavrou, S ;

Kleinberg, D ;

Klibanski, A .

CLINICAL ENDOCRINOLOGY, 2002, 57 (03) :385-390

[6] Standardized centile curves and reference intervals of serum insulin-like growth factor-I (IGF-I) levels in a normal Japanese population using the LMS method [J].

Isojima, Tsuyoshi ;

Shimatsu, Akira ;

Yokoya, Susumu ;

Chihara, Kazuo ;

Tanaka, Toshiaki ;

Hizuka, Naomi ;

Teramoto, Akira ;

Tatsumi, Ke-ita ;

Tachibana, Katsuhiko ;

Katsumata, Noriyuki ;

Horikawa, Reiko .

ENDOCRINE JOURNAL, 2012, 59 (09) :771-780

[7] Inhibition of Growth Hormone Receptor Activation by Pegvisomant may Increase Bone Density in Acromegaly [J].

Jimenez, C. ;

Ayala-Ramirez, M. ;

Liu, J. ;

Nunez, R. ;

Gagel, R. F. .

HORMONE AND METABOLIC RESEARCH, 2011, 43 (01) :55-61

[8] Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency [J].

Johannsson, G ;

Rosen, T ;

Bosaeus, I ;

Sjostrom, L ;

Bengtsson, BA .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (08) :2865-2873

[9] Bone metabolism and body composition in Japanese patients with active acromegaly [J].

Kaji, H ;

Sugimoto, T ;

Nakaoka, D ;

Okimura, Y ;

Kaji, H ;

Abe, H ;

Chihara, K .

CLINICAL ENDOCRINOLOGY, 2001, 55 (02) :175-181

[10] Growth hormone receptor antagonists: Discovery, development, and use in patients with acromegaly [J].

Kopchick, JJ ;

Parkinson, C ;

Stevens, EC ;

Trainer, PJ .

ENDOCRINE REVIEWS, 2002, 23 (05) :623-646

← 1 2 3 →